This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Spina Bifida with Hydrocephalus, Unspecified수두증을 동반한 상세불명의 이분척추 (수두증 반 상세불명 이분척추)

Contents and key points
ItemDetails
A. Classification codesICD-10: Q05.4 | Special Copayment Reduction: V179
B. Synonyms—
C. Adult onsetVery low — as a congenital spinal malformation, it is in principle diagnosed in the fetal or neonatal period; first onset in adulthood is extremely rare.
1. HistoryHistory of spina bifida; discovery of folic acid prevention (1991); MOMS fetal surgery trial (2011).
2. CausesFolate deficiency, multifactorial inheritance, maternal diabetes, obesity, anticonvulsants; hydrocephalus: Chiari II malformation.
3. GeneticsMTHFR, PCP pathway; multifactorial inheritance; recurrence risk 2–5%; high-dose folic acid prevention.
4. General epidemiology1 in 1,000–2,000 births; Special Copayment Reduction V179; slight sex difference.
5. PathophysiologyFailure of neural tube closure; two-hit theory; mechanisms of Chiari II malformation and hydrocephalus.
6. SymptomsLower limb paralysis (by level), hydrocephalus symptoms, neurogenic bladder and bowel
7. SignsCystic defect at the lesion site; neurological findings; signs of hydrocephalus (if present)
8. ScreeningMSAFP, detailed prenatal ultrasound (lemon and banana signs), fetal MRI.
9. DiagnosisPrenatal confirmation; postnatal neurological, imaging, urological, and orthopedic evaluation.
10. TreatmentSpinal cord closure (prenatal/postnatal); hydrocephalus shunt (if present); CIC; rehabilitation.
11. PrognosisVaries by lesion level; early hydrocephalus treatment and CIC management determine prognosis
12. PreventionFolic acid (general 400–800 μg; high-risk 4,000 μg); risk factor management.
13. ReferencesMitchell LE et al. 2004 and 9 other references

1. History

Spina bifida is one of the oldest congenital malformations in the history of human medicine. The term 'spina bifida' is known to have been first used in 1641 by the 17th-century Dutch physician Nicolaas Tulp (1593–1674), expressing in Latin the condition of a vertebra split in two. In the early 18th century, the Italian anatomist Giovanni Battista Morgagni described in detail the pathological anatomy of spina bifida and its association with hydrocephalus. In the 19th century, surgical treatment was attempted, but results were poor because of infection and technical limitations.

In the mid-20th century, the introduction of the ventriculoperitoneal shunt (VP shunt) and antibiotics dramatically improved treatment outcomes for spina bifida with hydrocephalus. In 1965, Hibbard and Smithells first proposed an association between folate deficiency and neural tube defects, and in 1991 the UK MRC Vitamin Study confirmed in a randomized controlled trial that folic acid supplementation before pregnancy reduces recurrence of neural tube defects by about 72%. Mandatory folic acid fortification of grain products was subsequently implemented in many countries, significantly lowering the incidence of spina bifida.

In prenatal diagnosis, the introduction of maternal serum alpha-fetoprotein (MSAFP) testing in 1972 and the spread of high-resolution prenatal ultrasound from the 1980s onward meant that most open spina bifida came to be diagnosed prenatally. The MOMS randomized controlled trial published in 2011 demonstrated that prenatal myelomeningocele closure (fetal surgery) significantly improves neurological outcome compared with postnatal surgery, shifting the paradigm of spina bifida treatment. Today, the worldwide standard for spina bifida management is collaboration among pediatric neurosurgery, neurology, urology, orthopedics, rehabilitation medicine, and developmental pediatrics within a multidisciplinary spina bifida clinic.

Thoracic/lumbar/sacral/unspecified spina bifida with hydrocephalus differ in clinical characteristics depending on lesion level, and each is classified under its own ICD-10 code (Q05.1–Q05.4). In Korea, multidisciplinary spina bifida clinics are also operated mainly at major children's hospitals, and registration under Special Copayment Reduction V179 allows medical cost support.


2. Causes

Spina bifida is a neural tube defect (NTD) caused by failure of the neural tube closure process in early pregnancy (about 17–30 days after fertilization, 5–6 weeks of gestation). Its causes are divided into genetic factors, maternal nutritional and metabolic factors, environmental factors, and multifactorial interactions.

Folate deficiency: folic acid deficiency in early pregnancy is the most important preventable risk factor for spina bifida. Folic acid is an essential nutrient for DNA synthesis, cell division, and one-carbon metabolism, and adequate folic acid intake before and in early pregnancy (400–800 μg per day; 4,000 μg for high-risk groups) lowers the incidence of spina bifida by about 50–70%.

Genetic factors: spina bifida is a multifactorial disease; the MTHFR 677C→T polymorphism, folate receptor gene variants, and variants in planar cell polarity (PCP) pathway genes (VANGL1, VANGL2, etc.) are associated with increased risk of spina bifida. With a family history, the recurrence risk is about 4–8 times that of the general population.

Maternal factors: maternal diabetes (poor glycemic control in early pregnancy), maternal obesity (BMI > 30), use of anticonvulsants (valproic acid, carbamazepine), and high fever in early pregnancy (38°C or higher) increase the risk of spina bifida.

Etiology of hydrocephalus: hydrocephalus arises through combined mechanisms including Chiari II malformation (herniation of the cerebellum and brainstem through the foramen magnum), aqueductal stenosis, and fourth ventricle outlet obstruction. The higher the lesion level, the more severe the Chiari II malformation and the higher the rate and severity of associated hydrocephalus.


3. Genetics

Spina bifida is a disease of multifactorial inheritance, arising from complex interactions of multiple genetic polymorphisms and environmental factors rather than a single gene mutation. The risk of recurrence within families is higher than in the general population, but it does not follow a typical Mendelian pattern of inheritance.

Folate metabolism genes: the MTHFR c.677C→T polymorphism (p.Ala222Val) reduces enzyme activity and raises blood homocysteine, increasing the risk of spina bifida about 1.5–2-fold. Variants in folate metabolism enzyme genes such as FOLR1 (folate receptor 1) and MTHFD1 are also associated with neural tube defects.

PCP pathway genes: VANGL1, VANGL2, CELSR1, FZD3, and others are essential for convergent extension movements during neural tube closure, and variants in these genes are found in about 1–3% of patients with spina bifida.

Recurrence risk: 1 child with spina bifida: recurrence risk in the next pregnancy about 2–5%. 2 affected: about 10–15%. One parent affected: about 4–8% for children. In high-risk groups, high-dose folic acid (4,000 μg/day) supplementation from before pregnancy greatly reduces the risk of recurrence.


4. General epidemiology

Spina bifida is the most common neural tube defect worldwide, occurring in about 1 in 1,000–2,000 births. Incidence by country differs greatly depending on folic acid supplementation policies and the rate of pregnancy termination after prenatal diagnosis. For spina bifida with hydrocephalus (Q05.0–Q05.4), hydrocephalus accompanies about 80–90% of all open spina bifida. The incidence in Korea is estimated at about 4–6 per 10,000 births, and registration under Special Copayment Reduction V179 allows medical cost support. Sex differences are slight, and it occurs in all ethnic groups worldwide.


5. Pathophysiology

Spina bifida arises from failure of neural tube closure at about 17–30 days of gestation; neural tube closure is a zipper-like process proceeding simultaneously from several initiation sites. The level of spina bifida (cervical/thoracic/lumbar/sacral) is determined by the site of closure failure. Two-hit hypothesis: ① the primary developmental defect due to failure of neural tube closure + ② secondary damage from exposure to amniotic fluid in utero cause the neurological impairment. Chiari II malformation arises from abnormal posterior fossa development due to herniation of the spinal cord and causes non-communicating hydrocephalus through impaired cerebrospinal fluid flow. Neurogenic bladder arises from loss of sacral nerve (S2–S4) function below the lesion.


6. Symptoms

Spina bifida, unspecified (Q05.4) includes spina bifida with hydrocephalus in which the lesion level is not clearly recorded, and clinical symptoms may vary across a spectrum from the cervical to the sacral level depending on the actual lesion level. Even when classified as unspecified, the clinician should confirm the patient's actual lesion level and take a clinical approach appropriate to that level.

Hydrocephalus symptoms: Symptoms due to raised intracranial pressure are common to all spina bifida with hydrocephalus. Infancy: rapid increase in head circumference (macrocephaly), bulging anterior fontanelle, dilated scalp veins, setting-sun sign, irritability, feeding difficulty. Childhood and later: headache (especially in the morning), nausea and vomiting, papilledema, diplopia, cognitive decline. When Chiari II malformation accompanies, dysphagia, apnea, and abnormal upper limb sensation may be added.

Motor and sensory dysfunction: Loss of motor function and sensory loss in the lower limbs or extremities occur according to the lesion level. Even when the lesion is not clearly recorded, the level of functional loss can be assessed by physical examination.

Neurogenic bladder and bowel: Neurogenic bladder and neurogenic bowel accompany most patients with spina bifida, and systematic management is needed regardless of whether hydrocephalus accompanies.

Other: Orthopedic problems such as spinal deformity (scoliosis, kyphosis), hip dislocation, and foot deformity, and skin care (pressure ulcer prevention) are important.


7. Signs

The signs of unspecified spina bifida differ according to the actual lesion level, and the following general findings are observed.

Hydrocephalus signs: Macrocephaly, bulging anterior fontanelle, sutural diastasis, dilated scalp veins, and the setting-sun sign appear in infants. With increasing age, papilledema, eye movement disorders, and headache become the main signs.

Neurological signs: Loss of motor function below the lesion level (paralysis or paresis), sensory loss, absent deep tendon reflexes, and absent anal reflex are observed. When Chiari II malformation accompanies, signs of brainstem compression (dysphagia, vocal cord paralysis, apnea) may be added.

Spinal and orthopedic signs: Confirm a cystic spinal defect (meningomyelocele or myelocele) and the site of the skin defect. With growth, scoliosis, hip dislocation, foot deformity, and leg length discrepancy may develop.

Imaging findings: MRI shows the location and size of the meningomyelocele or myelocele, Chiari II malformation, and ventricular dilatation due to hydrocephalus. Urological ultrasound evaluates hydronephrosis and bladder abnormalities.


8. Screening

Prenatal screening for spina bifida follows a stepwise approach: maternal serum alpha-fetoprotein (MSAFP, 15–22 weeks of gestation; positive threshold ≥ 2.0–2.5 MoM), detailed prenatal ultrasound at 18–22 weeks (spinal defect, lemon sign, banana sign, ventriculomegaly), and additional fetal MRI if abnormal. Prenatal ultrasound has a sensitivity of 95% or higher for detecting open spina bifida. Fetal MRI precisely assesses the lesion level, degree of Chiari II malformation, and severity of hydrocephalus, providing important information for surgical decisions and prognostic counseling. Amniotic fluid AFP and AChE testing is performed as an adjunct when ultrasound findings are unclear.


9. Diagnosis

Diagnosis of spina bifida is confirmed prenatally by a stepwise approach of prenatal MSAFP → detailed ultrasound → fetal MRI, and completed after birth by neurological evaluation, brain and spine MRI, urological evaluation, and orthopedic evaluation. Immediately after birth, motor and sensory function below the lesion level, the anal reflex, and bladder function are evaluated to establish the extent of loss of neurological function. Brain MRI identifies hydrocephalus, Chiari II malformation, and associated brain malformations, and spinal MRI evaluates the lesion level, tethered cord, and syringomyelia. Urodynamic testing characterizes the neurogenic bladder and determines the indications for starting CIC.


10. Treatment

Treatment of spina bifida with hydrocephalus requires a multidisciplinary approach including prenatal or postnatal spinal cord closure, hydrocephalus surgery (VP shunt or ETV), neurogenic bladder management (CIC, anticholinergics), orthopedic treatment, and neurodevelopmental support. Prenatal surgery (fetal surgery): based on the MOMS trial (2011), performed at 19–25 weeks of gestation in selected cases; it reverses Chiari II malformation, reduces the need for shunting, and improves lower limb motor function. Postnatal surgery: closure of the spinal defect within 24–48 hours. Treatment of hydrocephalus: VP shunt or ETV. Neurogenic bladder: CIC + anticholinergics (key to protecting renal function). Orthopedics: orthoses, surgical correction. Rehabilitation: physical therapy, occupational therapy, speech therapy, neuropsychological assessment, and learning support.


11. Prognosis

The prognosis of unspecified spina bifida (Q05.4) is determined by the actual lesion level and varies across a spectrum from cervical to sacral. In general, the higher the lesion level, the poorer the prognosis, and early treatment of hydrocephalus and appropriate management of neurogenic bladder play key roles in long-term prognosis.

Neurological prognosis: The lower the lesion level (sacral), the better the prognosis for lower limb function, independent ambulation, and cognitive function. If hydrocephalus is treated early and effectively, cognitive impairment is minimized. When there is brainstem compression related to Chiari II malformation, aggressive treatment (decompression surgery, etc.) is needed.

Renal function prognosis: Renal function can be protected by aggressive bladder management including CIC. Treatment adherence and regular follow-up are decisive for long-term renal function.

Survival: The 20-year survival rate of patients with spina bifida receiving modern multidisciplinary treatment is about 70–90% (varying with lesion level), and the main causes of death are shunt complications, respiratory failure (high lesions), and renal failure.


12. Prevention

The most effective primary prevention of spina bifida is folic acid supplementation before and in early pregnancy. General population: 400–800 μg daily from 1 month before pregnancy until 12 weeks of gestation. High-risk groups (previous NTD pregnancy, family history, diabetes, anticonvulsant use): high-dose 4,000 μg daily from before pregnancy until 12 weeks of gestation. Management of risk factors before pregnancy: glycemic control in maternal diabetes, obesity management, substitution or dose minimization of anticonvulsants such as valproic acid, and avoidance of high fever in early pregnancy. Prenatal care: MSAFP screening, detailed ultrasound, fetal MRI, and pregnancy and delivery planning with the multidisciplinary team. Prevention of complications: early surgery (spinal cord closure, shunting), early introduction of CIC, and regular multidisciplinary follow-up for early detection and management of shunt malfunction, spinal cord retethering, and urological complications.

13. References

  1. Mitchell LE, Adzick NS, Melchionne J, et al. Spina bifida. Lancet. 2004;364(9448):1885-1895. PMID: 15555669.
  2. Adzick NS, Thom EA, Spong CY, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med. 2011;364(11):993-1004. PMID: 21306277.
  3. Copp AJ, Stanier P, Greene NDE. Neural tube defects: recent advances, unsolved questions, and controversies. Lancet Neurol. 2013;12(8):799-810. PMID: 23790957.
  4. Northrup H, Volcik KA. Spina bifida and other neural tube defects. Curr Probl Pediatr. 2000;30(10):313-332. PMID: 11147289.
  5. Blount JP, Bowman R, Dias MS, et al. Neurosurgery in spina bifida. J Pediatr Rehabil Med. 2020;13(4):565-576. PMID: 33252094.
  6. Bowman RM, McLone DG, Grant JA, et al. Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg. 2001;34(3):114-120. PMID: 11359098.
  7. Liptak GS, Dosa NP. Myelomeningocele. Pediatr Rev. 2010;31(11):443-450. PMID: 21041162.
  8. Bol KA, Collins JS, Kirby RS. Survival of infants with neural tube defects in the presence of folic acid fortification. Pediatrics. 2006;117(3):803-813. PMID: 16510665.
  9. Jukic AM, Wilcox AJ, Lie RT, et al. Spina bifida and the risk of stillbirth in Norway. Am J Epidemiol. 2004;160(10):1001-1008. PMID: 15522861.
  10. Williams LJ, Rasmussen SA, Flores A, et al. Decline in the prevalence of spina bifida by race/ethnicity. Pediatrics. 2005;116(3):580-586. PMID: 16140698.